Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

VLA1553

Vaccine (Live attenuated vaccine) · Immune activation, directed at Chikungunya virus · developed by Valneva Austria GmbH

Phase 3 Most advanced trial

VALN Developer

4 Registered trials

What is VLA1553?

VLA1553 is a lyophilized live-attenuated vaccine against chikungunya virus, given as a single intramuscular injection. It is studied for prevention of chikungunya virus infection and the fever it causes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine (Live attenuated vaccine)
Targets: Chikungunya virus (antigen)
Mechanism: Immune activation, directed at Chikungunya virus
Therapy area: Infectious disease
Developer: Valneva Austria GmbH (VALN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04838444	Phase 3	Chikungunya Virus Infection	Active not recruiting	VALN
NCT04786444	Phase 3	Chikungunya Virus Infection	Completed	VALN
NCT06106581	Phase 2	Chikungunya Virus Infection	Completed	VALN
NCT07163845	N/A	Chikungunya Virus Infection	Active not recruiting	VALN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chikungunya Virus Infection

More from Valneva Austria GmbH

IC51 FDA approved Japanese encephalitis virus vaccine, inactivated FDA approved 3M-052-AF Phase 1 ChAdOx1 nCoV-19 Vaccine Phase 3 IC41 Phase 2 IC43 Phase 2/3 IC47 Phase 1 IC84 Phase 1 ISS 1018 CpG Oligodeoxynucleotide Phase 1 JE-VAX Phase 3 Pneumococcal 7-Valent Conjugate Vaccine Phase 3 VLA1601 Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the VALN page.

Follow VALN, the company behind VLA1553

See VALN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VALN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z